BOSULIF DIN 02419157
Status: Marketed
Holder: PFIZER CANADA ULC
Molecule: BOSUTINIB (BOSUTINIB MONOHYDRATE)
Available to quote
Health Canada record
| Active ingredient(s) | BOSUTINIB (BOSUTINIB MONOHYDRATE) 500 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EA04 BOSUTINIB |
| Original market date | 24-Mar-2014 |
| Current status date | 24-Mar-2014 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BOSUTINIB (BOSUTINIB MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02419149 | BOSULIF | PFIZER CANADA ULC | Tablet | BOSUTINIB (BOSUTINIB MONOHYDRATE) 100 MG | Marketed |
| 02483793 | BOSULIF | PFIZER CANADA ULC | Tablet | BOSUTINIB (BOSUTINIB MONOHYDRATE) 400 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15380 | 2014-03-07 | New Drug Submission (NDS) |